Infantile haemangiomas are the most common benign vascular tumours in childhood and occur in approximately 4% of children. IH is more common in low birth weight infants, female newborns, multiple gestations, pregnant women on progesterone therapy, and positive family history. The pathogenesis of IHs is not fully understood. The main cell of origin of IHs has been postulated to be endothelial progenitor cells derived from the chorionic villi of the placenta, supported by the common expression of placenta-associated antigens such as glucose transporter protein-1, merosin, FcgRII, and Lewis Y antigen, which are specifically expressed by chorionic villi. Vascular endothelial growth factor-A, which is involved in angiogenesis, may be an important driver of IH proliferation and may partially justify the response to corticosteroids and propranolol. In addition, the development of IHs has been reported to be associated with genetic factors located on chromosome 5q. The main goals of patient management in infantile hemangioma are to prevent life- or function-threatening complications, to treat ulceration, to protect from permanent structural disorders, and to reduce the psychological distress of the patient and the family. The currently available treatment regimens include oral medications, topical medications, injectable medications applied, and laser and surgical options. Among them, oral beta blockers have shown excellent curative effects. Sometimes, surgery is performed for reconstruction after the residual adipose fibrous phase.